Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial

BACKGROUND: Twelve months of oral cyclophosphamide (CYC) has been shown to alter the progression of scleroderma-related interstitial lung disease (SSc-ILD) when compared to placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Respir Med
Main Authors: Tashkin, Donald P, Roth, Michael D, Clements, Philip J, Furst, Daniel E, Khanna, Dinesh, Kleerup, Eric C, Goldin, Jonathan, Arriola, Edgar, Volkmann, Elizabeth R, Kafaja, Suzanne, Silver, Richard, Steen, Virginia, Strange, Charlie, Wise, Robert, Wigley, Fredrick, Mayes, Maureen, Riley, David J, Hussain, Sabiha, Assassi, Shervin, Hsu, Vivien M, Patel, Bela, Phillips, Kristine, Martinez, Fernando, Golden, Jeffrey, Connolly, M Kari, Varga, John, Dematte, Jane, Hinchcliff, Monique, Fischer, Aryeh, Swigris, Jeffrey, Meehan, Richard, Theodore, Arthur, Simms, Robert, Volkov, Suncica, Schraufnagel, Dean E, Scholand, Mary Beth, Frech, Tracy, Molitor, Jerry A, Highland, Kristin, Read, Charles A, Fritzler, Marvin J, Kim, Grace Hyun J, Tseng, Chi-Hong, Elashoff, Robert M
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5014629/
https://ncbi.nlm.nih.gov/pubmed/27469583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(16)30152-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados